The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer

Trastuzumab is the first-line targeted therapeutic drug for HER2-positive breast cancer, leading to improved overall survival. However, acquired resistance inevitably occurs. We aimed to identify, quantify, and assess the mechanisms of acquired resistance to trastuzumab. We established an acquired t...

Full description

Bibliographic Details
Main Authors: Paula González-Alonso, Sandra Zazo, Ester Martín-Aparicio, Melani Luque, Cristina Chamizo, Marta Sanz-Álvarez, Pablo Minguez, Gonzalo Gómez-López, Ion Cristóbal, Cristina Caramés, Jesús García-Foncillas, Pilar Eroles, Ana Lluch, Oriol Arpí, Ana Rovira, Joan Albanell, Sander R. Piersma, Connie R. Jimenez, Juan Madoz-Gúrpide, Federico Rojo
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Cancers
Subjects:
breast cancer
anti-receptor therapy
trastuzumab
resistance
Hippo pathway
YAP1
Online Access:https://www.mdpi.com/2072-6694/12/5/1108

Internet

https://www.mdpi.com/2072-6694/12/5/1108

Similar Items